Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of Palifermin for Prevention of Chemoradiotherapy-Induced Dysphagia in Unresectable Stage III NSCLC
2004-003116-33Phase 2Completed
- Sponsor
- Sobi
- Start
- Sep 2005
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2 trial of palifermin in non-small cell lung cancer (NSCLC), sponsored by Sobi. Primary endpoint: Incidence of dysphagia grade ≥ 2. Started Sep 2005; status: completed.
02
Drugs
palifermin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2004-003116-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-003116-33.